STOCK TITAN

BIOPHYTIS SA SP/ADR - BPTSY STOCK NEWS

Welcome to our dedicated page for BIOPHYTIS SA SP/ADR news (Ticker: BPTSY), a resource for investors and traders seeking the latest updates and insights on BIOPHYTIS SA SP/ADR stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BIOPHYTIS SA SP/ADR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BIOPHYTIS SA SP/ADR's position in the market.

Rhea-AI Summary

Biophytis SA (FP: ALBPS), a clinical-stage biotechnology company focused on age-related disease treatments, has announced its participation in the upcoming Biomed Forum organized by All Invest Securities. The event, scheduled for February 4, 2025 in Paris, is an annual healthcare sector conference that connects biotech and medtech companies with institutional investors. During the forum, Biophytis will have the opportunity to engage with French and European investors, provide company updates, and present its 2025 outlook.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Biophytis SA (BPTSY) has signed a co-development agreement with AskHelpU, China's largest ALS patient association, to evaluate the efficacy of BIO101, Biophytis' lead drug candidate, for Amyotrophic Lateral Sclerosis (ALS) treatment. The collaboration will leverage Biophytis' drug expertise and AskHelpU's disease knowledge, with research conducted at top Chinese universities.

BIO101, currently being developed for sarcopenia and obesity, could potentially offer a therapeutic solution for ALS, a severe neuromuscular disease affecting approximately 200,000 patients in China. ALS causes gradual muscle paralysis and affects speech and swallowing functions, with no current curative treatment available.

AskHelpU, founded in 2019 by former JD.com Vice President Cai Lei, has connected over 15,000 people across China and aims to help over one million people affected by neurodegenerative diseases. The organization has received significant funding, including a recent 100 million RMB donation announced in early 2024 for basic research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Biophytis SA (OTC Pink: BPTSY) has entered exclusive negotiations with a leading Chinese pharmaceutical company to establish a licensing agreement for BIO101 (20-Hydroxyecdysone). The agreement aims to co-develop and commercialize BIO101 in China for treating viral respiratory infections, sarcopenia, and obesity.

The potential partner is part of a major Chinese group with expertise in innovative technologies and access to China's rapidly growing market. This development follows Biophytis' partnership strategy, building on their previous agreement with Blanver for the LATAM region. The Chinese market represents a significant opportunity, with 70 million obesity patients and 30 million sarcopenia patients. China is currently the second-largest pharmaceutical market globally, valued at $190 billion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.11%
Tags
none

FAQ

What is the current stock price of BIOPHYTIS SA SP/ADR (BPTSY)?

The current stock price of BIOPHYTIS SA SP/ADR (BPTSY) is $2.78 as of February 7, 2025.

What is the market cap of BIOPHYTIS SA SP/ADR (BPTSY)?

The market cap of BIOPHYTIS SA SP/ADR (BPTSY) is approximately 4.9M.
BIOPHYTIS SA SP/ADR

OTC:BPTSY

BPTSY Rankings

BPTSY Stock Data

4.93M
52.42k
0.21%
3.22%
Biotechnology
Healthcare
Link
France
Paris